Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007870 | 0.89 | LMNA (0.57) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL31327382 | 0.89 | LMNA (0.64) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL31526782 | 0.87 | LMNA (0.61) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL2248076 | 0.86 | HCAR3 (0.74) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL5315342 | 0.84 | MAPT (0.81) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL1306790 | 0.84 | MAPT (0.65) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL22121338 | 0.84 | HCAR3 (0.59) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL2421954 | 0.83 | MAPT (0.60) | LMNAMAPTALDH1A1PKMHCAR3 | |
| SCHEMBL16449995 | 0.83 | LMNA (0.60) | LMNAMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL2252228 | 0.83 | MAPT (0.82) | LMNAMAPTALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1994002-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102767-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | LMNA 3005/4885MAPT 3059/4885ALDH1A1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.